Fangfang Liu

1.3k total citations · 1 hit paper
46 papers, 893 citations indexed

About

Fangfang Liu is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Fangfang Liu has authored 46 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Organic Chemistry. Recurrent topics in Fangfang Liu's work include Microbial Natural Products and Biosynthesis (5 papers), Cancer-related Molecular Pathways (3 papers) and RNA modifications and cancer (3 papers). Fangfang Liu is often cited by papers focused on Microbial Natural Products and Biosynthesis (5 papers), Cancer-related Molecular Pathways (3 papers) and RNA modifications and cancer (3 papers). Fangfang Liu collaborates with scholars based in China, United States and Germany. Fangfang Liu's co-authors include Zigang Dong, Kangdong Liu, Hanyong Chen, Qiong Wu, Ann M. Bode, Ke‐Qin Zhang, Dong Joon Kim, Mee‐Hyun Lee, Mengqiu Song and Guo-Hong Li and has published in prestigious journals such as SHILAP Revista de lepidopterología, Oncogene and Human Molecular Genetics.

In The Last Decade

Fangfang Liu

45 papers receiving 880 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrins in cancer: Emerging mechanisms and therapeutic opportunities

2023 88 citations Fangfang Liu, Qiong Wu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fangfang Liu China	19	381	167	115	105	95	46	893
Fanying Meng China	18	333 0.9×	145 0.9×	231 2.0×	81 0.8×	58 0.6×	57	841
Yao Fong Taiwan	16	334 0.9×	96 0.6×	102 0.9×	96 0.9×	66 0.7×	28	780
Sun‐Mi Yun South Korea	17	484 1.3×	117 0.7×	97 0.8×	98 0.9×	36 0.4×	35	855
Weijian Zhang China	16	350 0.9×	106 0.6×	117 1.0×	150 1.4×	52 0.5×	52	1.0k
Haiming Ding United States	15	514 1.3×	162 1.0×	79 0.7×	76 0.7×	100 1.1×	30	898
Mei Zhang China	17	334 0.9×	133 0.8×	143 1.2×	75 0.7×	56 0.6×	54	842
Vitale Del Vecchio Italy	16	273 0.7×	136 0.8×	113 1.0×	74 0.7×	100 1.1×	30	731
Sei‐Hoon Yang South Korea	19	486 1.3×	126 0.8×	99 0.9×	178 1.7×	63 0.7×	42	1.0k
Nils H. Thoennissen Germany	21	587 1.5×	193 1.2×	99 0.9×	105 1.0×	44 0.5×	37	1.3k

Countries citing papers authored by Fangfang Liu

Since Specialization

Citations

This map shows the geographic impact of Fangfang Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangfang Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangfang Liu more than expected).

Fields of papers citing papers by Fangfang Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fangfang Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangfang Liu. The network helps show where Fangfang Liu may publish in the future.

Co-authorship network of co-authors of Fangfang Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Fangfang Liu. A scholar is included among the top collaborators of Fangfang Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangfang Liu. Fangfang Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Fangfang, et al.. (2025). Development of a five-axis high-stability (50nrad) mirror system for the beamline at The Shanghai HIgh repetitioN rate XFEL and extreme light facility (SHINE). Measurement. 248. 116905–116905. 1 indexed citations

Jia, Xuechao, Chuntian Huang, Fangfang Liu, Zigang Dong, & Kangdong Liu. (2024). Elongation factor 2 in cancer: a promising therapeutic target in protein translation. Cellular & Molecular Biology Letters. 29(1). 156–156. 1 indexed citations

Pladevall, Manel, Catherine B. Johannes, J. Bradley Layton, et al.. (2024). FOUNTAIN: a modular research platform for integrated real-world evidence generation. BMC Medical Research Methodology. 24(1). 224–224. 4 indexed citations

Kövesdy, Csaba P., J. Bradley Layton, Gary C. Curhan, et al.. (2024). #2022 Clinical outcomes in US patients initiating finerenone – a report from the FOUNTAIN platform. Nephrology Dialysis Transplantation. 39(Supplement_1). 1 indexed citations

Sato, Atsuhisa, Daloha Rodríguez-Molina, Satoshi Yamashita, et al.. (2024). Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform. Journal of Clinical Medicine. 13(17). 5107–5107. 7 indexed citations

Geng, Liang, Fangfang Liu, Liyun Yang, Yan Liu, & Guang Wu. (2024). USP18 promotes the proliferation, invasion, and migration of head and neck squamous cell carcinoma by deubiquitinating PLK1. Experimental Cell Research. 442(2). 114284–114284.

Zhang, Kaihui, Chuan Wang, Mohnad Abdalla, et al.. (2024). Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy. Human Molecular Genetics. 33(13). 1120–1130. 4 indexed citations

Liu, Fangfang, et al.. (2022). A decision support system for primary headache developed through machine learning. PeerJ. 10. e12743–e12743. 16 indexed citations

Wen, Zewen, Fangfang Liu, Peixing Zhang, et al.. (2022). In vitro activity and adaptation strategies of eravacycline in clinical Enterococcus faecium isolates from China. The Journal of Antibiotics. 75(9). 498–508. 3 indexed citations

10.

Hu, Yamei, Fangfang Liu, Xuechao Jia, et al.. (2021). Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3. Oncogene. 40(23). 3942–3958. 15 indexed citations

11.

Li, Ke, et al.. (2021). Genomic analysis of host gene responses to cerebral Plasmodium falciparum malaria. Immunity Inflammation and Disease. 9(3). 819–826. 3 indexed citations

12.

Jia, Xuechao, Chuntian Huang, Yamei Hu, et al.. (2021). Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo. Journal of Experimental & Clinical Cancer Research. 40(1). 105–105. 27 indexed citations

13.

Tian, Xueli, Kangdong Liu, Zhi Li, et al.. (2019). 3,3'-Diindolylmethane inhibits patient-derived xenograft colon tumor growth by targeting COX1/2 and ERK1/2. Cancer Letters. 448. 20–30. 36 indexed citations

14.

Song, Mengqiu, Xuejiao Liu, Kangdong Liu, et al.. (2018). Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo. Molecular Cancer Therapeutics. 17(7). 1540–1553. 73 indexed citations

15.

DeWane, Michael P., et al.. (2018). A propensity score matched comparison of readmissions and cost of laparoscopic cholecystectomy vs percutaneous cholecystostomy for acute cholecystitis. The American Journal of Surgery. 217(1). 83–89. 13 indexed citations

16.

Lim, Tae‐Gyu, Sungyoung Lee, Mee‐Hyun Lee, et al.. (2017). The Prolyl Isomerase Pin1 Is a Novel Target of 6,7,4′-Trihydroxyisoflavone for Suppressing Esophageal Cancer Growth. Cancer Prevention Research. 10(5). 308–318. 18 indexed citations

17.

Liu, Fangfang, Wenli Li, Jürgen Pauluhn, H Trübel, & Chen Wang. (2013). Rat models of acute lung injury: Exhaled nitric oxide as a sensitive, noninvasive real-time biomarker of prognosis and efficacy of intervention. Toxicology. 310. 104–114. 12 indexed citations

18.

Li, Guo-Hong, et al.. (2011). A new sesquiterpene from endophytic fungusAspergillussp.. Natural Product Research. 26(14). 1334–1338. 6 indexed citations

19.

Liu, Fangfang, et al.. (2010). Two New Sesquiterpenes from the Fungus Stereum sp.. Helvetica Chimica Acta. 93(9). 1737–1741. 19 indexed citations

20.

Zhang, Anding, Meilin Jin, Fangfang Liu, et al.. (2006). Development and Evaluation of a DAS-ELISA for Rapid Detection of Avian Influenza Viruses. Avian Diseases. 50(3). 325–330. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact